文献速递肝胆胰外科胃肠外科

BRAF突变驱动结直肠癌肝转移根治性切除后早期多灶肝内复发

BRAF Mutation Drives Early Multifocal Intrahepatic Recurrence after Curative Resection of Liver-Limited Colorectal Metastases.
PubMed 文献 · J Am Coll Surg · 2026-03-26

这项国际多中心回顾性研究纳入2000至2023年间接受根治性肝切除的肝局限性结直肠癌肝转移成人患者1729例,评估KRAS/BRAF突变与复发部位及时间的关系。BRAF突变独立关联肝内和肝外复发,KRAS仅关联肝外复发,两者均与早期复发相关且BRAF风险更高。BRAF突变者肝内早期复发时病灶数更多,肝内复发后总生存更差。

要点

  • BRAF突变者肝内复发风险显著升高(HR 3.47),且早期复发风险高于KRAS。
  • BRAF突变肝内早期复发时病灶数量更多,提示多灶性复发模式。
  • 肝内复发后伴任何驱动突变者总生存更差,支持BRAF突变者强化肝脏监测。

核心结论

  • BRAF突变是结直肠癌肝转移根治性切除后早期多灶肝内复发和术后生存不良的独立标志物。
  • BRAF突变与肝内和肝外复发均独立相关,而KRAS突变仅与肝外复发相关。
  • BRAF和KRAS突变均与早期复发相关,其中BRAF突变的风险最高。

研究设计与样本

  • 国际多中心数据库回顾性队列研究,纳入2000至2023年接受根治性肝局限性结直肠癌肝转移切除的成人患者1729例。
  • 采用多变量Cox比例风险模型和logistic回归评估KRAS/BRAF状态与首发复发部位及复发时间的关联。

主要发现

  • KRAS突变287例(16.7%),BRAF突变43例(2.5%)。
  • 复发为肝内537例(31.1%),肝外288例(16.7%),无复发904例(52.3%)。
  • BRAF突变独立关联肝内复发(HR 3.47,95%CI 1.61–7.51,p=0.001)和肝外复发(HR 3.63,95%CI 1.12–11.79,p=0.032)。
  • KRAS突变仅关联肝外复发(HR 3.07,95%CI 1.64–5.75,p=0.001)。
  • BRAF突变(OR 3.69,95%CI 1.20–11.33,p=0.023)和KRAS突变(OR 2.50,95%CI 1.41–4.43,p=0.003)均与早期复发相关,BRAF风险最高(p<0.001 vs KRAS)。

临床怎么用

  • 对BRAF突变结直肠癌肝转移根治性切除患者,应考虑强化肝脏-focused surveillance(以肝脏为中心的监测)。
  • BRAF突变患者可考虑早期联合辅助治疗。
  • BRAF突变者肝内复发常为多灶性,监测时需关注多发病灶。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: BRAF mutations occur in only 2% to 5% of patients undergoing hepatectomy for colorectal liver metastases (CRLM), and their mutation-specific recurrence patterns-especially in comparison with KRAS -remain poorly defined. STUDY DESIGN: An international, multi-institutional database was queried for adults who underwent curative-intent resection of liver-limited CRLM between 2000 and 2023 (N = 1,729). Multivariable Cox proportional hazards and logistic regression models assessed the association between KRAS / BRAF status and (1) first-site recurrence (intrahepatic vs extrahepatic) and (2) timing of recurrence (early less than 12 months vs late 12 months or more). RESULTS: KRAS and BRAF mutations were present in 287 (16.7%) and 43 (2.5%) patients, respectively. Relapse was intrahepatic in 537 (31.1%) patients, extrahepatic in 288 (16.7%), and absent in 904 (52.3%). BRAF mutation was independently associated with both intrahepatic (hazard ratio [HR] 3.47, 95% CI 1.61 to 7.51, p = 0.001) and extrahepatic recurrence (HR 3.63, 95% CI 1.12 to 11.79, p = 0.032), whereas KRAS mutation was associated only with extrahepatic relapse (HR 3.07, 95% CI 1.64 to 5.75; p = 0.001). Both BRAF (odds ratio 3.69, 1.20 to 11.33; p = 0.023) and KRAS (odds ratio 2.50, 95% CI 1.41 to 4.43; p = 0.003) mutations were linked to early recurrence, with the highest risk observed for BRAF (p < 0.001 vs KRAS ). In early intrahepatic relapse, BRAF -mutant tumors recurred with a greater number of lesions (β = 3.12; p = 0.012) but similar lesion size compared with other genotypes. Overall survival after intrahepatic relapse was worse in the presence of any driver mutation (p = 0.018), whereas survival after extrahepatic relapse was unaffected by genotype (p = 0.470). CONCLUSIONS: BRAF mutation-unlike KRAS -emerged as a powerful, independent marker of early, multifocal intrahepatic recurrence and inferior post-hepatectomy survival in CRLM. These findings support intensified liver-focused surveillance and early combination adjuvant therapy for patients with BRAF -mutant disease.

来源:J Am Coll Surg,查看原文。版权归原作者所有。

引用

  1. Akabane M, Baldo A, Kawashima J, et al. BRAF Mutation Drives Early Multifocal Intrahepatic Recurrence after Curative Resection of Liver-Limited Colorectal Metastases. J Am Coll Surg. 2026. PMID: 41532624. doi:10.1097/XCS.0000000000001748

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。